Regeneron has made a concerted effort ... A peak at phase 1 data of ubamatamab, a bispecific antibody targeting MUC16 and CD3, showed that it held promise among some of the sickest patients.

Regeneron’s other costimulatory bispecific development programs, which include candidates against EGFR, MUC16 and CD22, are unaffected and are still making their way through dose escalation.

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the ...

10, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals ... ubamatamab is a CD3-targeting bispecific under investigation for recurrent ovarian cancer and designed to bridge MUC16 on cancer cells with ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Regeneron has moved closer to a regulatory filing for its BCMAxCD3 bispecific antibody linvoseltamab, the first of a series of bispecifics that is spearheading its oncology pipeline. New data from ...

Regeneron’s Lynozyfic is a bispecific antibody that works by bridging B-cell maturation antigen on MM cells with CD3-expressing T cells to drive T-cell activation and cancer-cell killing. The drug can ...

4, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals ... including a mini-oral on the CD3-targeting bispecific ubamatamab (designed to bridge MUC16 on cancer cells with CD3-expressing T cells ...

ubamatamab is a CD3-targeting bispecific under investigation for recurrent ovarian cancer and designed to bridge MUC16 on cancer cells with CD3-expressing T cells to facilitate local T-cell ...